Production of human polyclonal antibodies by transgenic animals
Louis-Marie Houdebine
DOI: 10.4236/abb.2011.23022   PDF   HTML   XML   7,450 Downloads   14,484 Views   Citations


Polyclonal antibodies collected from the blood of animals and humans experimentally immunised or spontaneously immunised respectively can be injected into patients to protect them against pathogens, toxins, tumours etc. This approach is severely limited by the availability of human polyclonal antibodies of interest. Moreover, polyclonal antibodies from animals are recognised as antigens by patients and are thus rapidly rejected and inactivated. To circumvent this problem, animals (essentially rabbits, chicken, pigs and cows) are being genetically engineered. Their immunoglobulin genes are being inactivated and the corresponding human immunoglobulin genes are being transferred to them. These animals will be immunized and it is expected that large amounts of pure human polyclonal antibodies will be extracted from their blood to be administered to patients. The possible acceptability problem of this approach is under a case study of the European Union Pegasus project.

Share and Cite:

Houdebine, L. (2011) Production of human polyclonal antibodies by transgenic animals. Advances in Bioscience and Biotechnology, 2, 138-141. doi: 10.4236/abb.2011.23022.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Houdebine, L.M. (2009) Production of pharmaceutical proteins by transgenic animals. Comparative Immuno- logy, Microbiology & Infectious Diseases, 32, 107-121. doi:10.1016/j.cimid.2007.11.005
[2] Rehbinder, E., et al. (2009) Pharming. Promises and risks of biopharmaceuticals derived from genetically modified plants and animals. Springer-Verlag, Berlin.
[3] Zhu, L., et al. (2005) Production of human monoclonal antibody in eggs of chimeric chickens. Nature Biote- chnolology, 23, 1159-1169.
[4] Lonberg, N. (2005) Human antibodies from transgenic animals. Nature Biotechnology, 23, 1117-1125. doi:10.1038/nbt1135
[5] Kuroiwa, Y., et al. (2009) Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Na- ture Biotechnology, 27, 173-181. doi:10.1038/nbt.1521
[6] Geurts, A.M., et al. (2009) Knockout rats via embryo microinjection of zinc-finger nucleases. Science, 325, 433. doi:10.1126/science.1172447
[7] Boch, J. (2011) TALEs of genome targeting. Nature Bio- technology, 29, 135-136. doi:10.1038/nbt.1767
[8] Kuroiwa, Y., et al. (2004) Sequential targeting of the genes encoding immunoglobulin-μ ?and prion protein in cattle. Nature Genetics, 36, 775-780. doi:10.1038/ng1373
[9] Richt, J.A., et al. (2007) Production of cattle lacking prion protein. Nature Biotechnology, 25, 132-138. doi:10.1038/nbt1271
[10] Newcombe, C. and Newcombe, A.R. (2007) Antibody production: polyclonal-derived biotherapeutics. Journal of Chromatography B, 848, 2-7. doi:10.1016/j.jchromb.2006.07.004
[11] Mendicino, M., et al. (2011) Generation of antibody- and B cell-deficient pigs by targeted disruption of the J-re- gion gene segment of the heavy chain locus. Transgenic Research, 20, 625-641. doi:10.1007/s11248-010-9444-z
[12] Ramsoondar, J., et al. (2011) Targeted disruption of the porcine immunoglobulin kappa light chain locus. Trans- genic Research, 20, 643-653. doi:10.1007/s11248-010-9445-y
[13] Flisikowska, T., et al. (2011) Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS ONE (in press).
[14] Leighton, P. and Etches, R. (2007) Human polyclonal antibodies from transgenic chickens.
[15] Keefer, C.L., Pommer, J. and Robl, J.M. (2007) The role of transgenic livestock in the treatment of human disease. Council for Agriculture Science and Technology, 35, 1-12.
[16] Buelow, R. and van Schooten, W. (2007) Ernst schering foundation symposium proceedings, Springer-Verlag, Berlin.
[17] Echelard, Y. (2009) Year of the ox. Nature Biotechnology, 27, 146-147. doi:10.1038/nbt0209-146
[18] Houdebine, L.M. (2010) Meeting report UC Davis transgenic animal research conference VII. Transgenic Research, 19, 127-130. doi:10.1007/s11248-009-9325-5

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.